ALT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Altimmune Inc (ALT) is not a strong buy for a beginner investor with a long-term strategy at this time. While analysts have a positive outlook with a $20 price target, the company's financial performance is weak, and technical indicators do not suggest a strong entry point. The lack of recent positive news or significant catalysts further supports a hold recommendation.
The MACD is negatively expanding below 0, indicating bearish momentum. RSI is at 29.881, in the neutral zone but near oversold levels. Moving averages are converging, signaling indecision in price trends. The stock is trading below its pivot level (5.076) and closer to its support level (S1: 4.587), suggesting limited upward momentum.
Barclays initiated coverage with an Overweight rating and a $20 price target, citing undervaluation in the biotech sector and potential tailwinds like mergers and acquisitions.
The stock has shown a consistent decline in recent trading sessions, with a -1.30% regular market change and -2.63% post-market change. Financial performance is weak, with declining net income (-16.77% YoY) and EPS (-34.38% YoY). No recent news or significant insider/hedge fund activity to support a bullish case.
In Q3 2025, revenue remained flat (0.00% YoY), while net income dropped significantly (-16.77% YoY) and EPS declined by -34.38% YoY. Gross margin remained stable at 100%. Overall, the financials indicate a lack of growth and profitability challenges.
Barclays initiated coverage with an Overweight rating and a $20 price target. The analyst views the biotech sector positively due to undervaluation and potential industry tailwinds, but this optimism is not yet reflected in Altimmune's performance.
